Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Oct 29, 2014
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Proteon Therapeutics Inc
| 1.43M |
$8.98 | -$560,380.00 |
∞
| 1.43M |
Oct 27
| |||||||
Proteon Therapeutics Inc
|
0
|
—
|
—
|
—
|
0
| ||||||||
Tetraphase Pharmaceuticals Inc
| -295.51K |
—
|
—
| -13.49% | 1.89M |
Mar 12
| |||||||
Acelrx Pharmaceuticals Inc
| -1.30M |
—
|
—
| -31.16% | 2.87M |
Mar 7
| |||||||
Concert Pharmaceuticals, Inc.
| 1.18M |
$14.00 |
—
| +3,634.46% | 1.21M |
Feb 20
| |||||||
Concert Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Tetraphase Pharmaceuticals Inc
| 2.18M |
$7.00 |
—
| +21,071.05% | 2.19M |
Mar 25
| |||||||
Tetraphase Pharmaceuticals Inc
|
0
|
—
|
—
|
—
|
0
| ||||||||
Acelrx Pharmaceuticals Inc
| 284.7K |
$3.40 | $967,973.20 | +7.34% | 4.16M |
May 29
| |||||||
Acelrx Pharmaceuticals Inc
| 3.89M |
$5.00 | $6,179,715.00 | +147.17% | 6.53M |
Feb 16
| |||||||
Acelrx Pharmaceuticals Inc
|
0
|
—
|
—
|
—
|
0
| ||||||||
Arca Biopharma, Inc.
| -50.60K |
$3.86 | -$195,287.21 | -13.11% | 335.4K |
Jun 11 - Jun 15
| |||||||
Arca Biopharma, Inc.
| -149.21K |
$4.08 | -$608,227.96 | -27.88% | 386K |
Jun 8 - Jun 10
| |||||||
Arca Biopharma, Inc.
| -342.38K |
—
|
—
| -39.01% | 535.21K |
Jun 1
| |||||||
Targanta Therapeutics Corp.
| -2.22M |
—
|
—
| -100.00% |
0
|
Feb 25
| |||||||
Arca Biopharma, Inc.
|
0
|
—
|
—
|
—
|
0
| ||||||||
Targanta Therapeutics Corp.
|
0
|
—
|
—
|
—
|
0
| ||||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. |